Fatigue: The Exhaustion That Outlasts Rest

What it is

Fatigue is the subjective sense of exhaustion, depleted energy, and weariness that is out of proportion to recent exertion and not relieved by ordinary rest. It is one of the most common symptoms in all of medicine and one of the most disabling, yet it remains among the least understood. A first essential step is to distinguish fatigue from two things it is often confused with: sleepiness (the drive to fall asleep, a separate system discussed in the sleeplessness document) and weakness (a measurable loss of muscle power). A person can be exhausted without being sleepy and without any loss of strength — which already tells us that fatigue is generated largely by the brain, not the muscles.

Subtypes and dimensions

Several distinctions organize this messy territory. Physical fatigue (the body feels heavy and depleted) is separated from mental or cognitive fatigue (concentration drains quickly, thinking feels effortful). Peripheral fatigue originates in muscle, while central fatigue is generated within the central nervous system — and most of the chronic, disabling fatigue seen in psychiatric and neurological conditions is central. It is also worth distinguishing fatigue, the felt state, from fatigability, the measurable decline in performance over sustained effort, and acute, protective fatigue (which sensibly tells us to rest) from the chronic, pathological fatigue that persists regardless of rest.

Where it appears

Fatigue is profoundly transdiagnostic. It is a core symptom of depression, multiple sclerosis, cancer and its treatment, fibromyalgia, autoimmune diseases such as lupus, anemia, thyroid disease, sleep disorders, and many medications. It is the defining feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and one of the most common and persistent symptoms of long COVID. This breadth is a clue: fatigue is likely a shared output of several different underlying disturbances rather than a single disease.

The neurobiology

The mechanisms of central fatigue are still incompletely understood — a fact worth stating plainly rather than papering over. That said, several converging accounts have real support.

The most influential is inflammation and "sickness behavior." When the body mounts an immune response, inflammatory signaling molecules (cytokines) act on the brain to produce a coordinated, evolutionarily ancient state — fatigue, social withdrawal, reduced appetite, and loss of interest — that conserves energy for fighting infection (Dantzer; Miller). The clearest demonstration is that giving people the inflammatory drug interferon-alpha reliably induces fatigue and depression. Crucially, cytokines act in part by reducing dopamine in the basal ganglia, which links fatigue directly to the effort-and-reward machinery behind anhedonia and low motivation — fatigue may partly be an effort-cost signal, the brain reporting that action is not worth the energy.

A second account emphasizes cellular energy. The mitochondria that produce the body's chemical fuel may function inefficiently in some fatigue states, a "bioenergetic" hypothesis explored in ME/CFS and depression that connects to the mitochondrial dysfunction account and to interest in energy-supporting compounds such as creatine. Additional contributors include HPA-axis (stress hormone) dysregulation, autonomic nervous system imbalance, disrupted sleep and circadian rhythms, and the direct effects of the underlying disease.

Why it matters

Fatigue is one of the symptoms most likely to remain after depression is otherwise treated, and this residual fatigue predicts relapse — so leaving it unaddressed is not benign. Because it is invisible and hard to measure, "medically unexplained" fatigue is often met with skepticism, which adds the burden of disbelief to the burden of exhaustion. Taking fatigue seriously as a real, brain-based symptom is itself part of good care.

Assessment: the reversible causes

For a knowledgeable reader, the practical priority is recognizing the reversible contributors that a workup should check, because several are common and treatable: anemia, thyroid dysfunction, vitamin B12 and vitamin D deficiency, obstructive sleep apnea, medication side effects, and depression. This mirrors the "detect treatable contributors" logic that runs through the neuroendocrine and metabolic biomarker document — these markers do not explain all fatigue, but missing one of them means missing an easy fix.

Treatment

Where an underlying cause is found, treating it comes first. Beyond that, the options are honestly limited.

Behavioral and rehabilitative approaches include energy management ("pacing"), sleep and circadian regulation, and, in some conditions, graded increases in activity.

Pharmacologically, wakefulness-promoting agents such as modafinil and stimulants such as methylphenidate help some people but have decidedly mixed trial evidence; notably, a rigorous trial in multiple sclerosis found amantadine, modafinil, and methylphenidate no better than placebo for MS fatigue. Treating co-occurring depression can help. Bioenergetic approaches such as creatine are of growing interest but remain unproven for fatigue specifically. There is, at present, no reliably effective drug for chronic fatigue in most conditions, and especially not for ME/CFS, where no pharmacotherapy is proven.

How it connects

Fatigue is the energy-and-effort sibling of anhedonia and low motivation — all three converge on the dopamine-driven effort calculation and on inflammation's sickness-behavior program. It links to the mitochondrial and metabolic accounts through cellular energy, to sleep and circadian regulation, and to the reversible-contributor logic of the diagnostics series.

Caveats

Distinguishing fatigue from sleepiness, weakness, and apathy is the first discipline, since each points elsewhere. Fatigue is subjective and hard to quantify, which fuels unwarranted skepticism. The ME/CFS and long COVID space is genuinely contested, lacks proven drug treatment, and — most importantly — is a setting where well-intentioned but inappropriate exercise advice can cause harm. And "medically unexplained" should be read as "not yet explained," not as "not real."

Bottom line

Fatigue is brain-generated exhaustion that outlasts rest — most often a central rather than a muscular problem, shaped by inflammation's energy-conserving sickness response, by cellular energy supply, and by the same effort-and-reward circuitry that underlies anhedonia and low motivation. It is common, disabling, frequently residual after other symptoms improve, and too often dismissed. The sensible approach is to find and treat the reversible causes, to match activity strategies carefully to the specific condition — pacing rather than pushing where post-exertional malaise is present — and to hold realistic expectations of the available medications while taking the symptom, and the person, seriously.

Selected references

1. Dantzer R, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008.
2. Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004.
3. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016.
4. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011.
5. Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology. 2013.
6. Nourbakhsh B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial (TRIUMPHANT-MS). Lancet Neurol. 2021.
7. Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities. Front Med. 2023.
8. National Institute for Health and Care Excellence (NICE). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206). 2021.
9. Manjaly ZM, et al. Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019.
10. Penninx BWJH, et al. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 2013.
11. Billones R, et al. Dissecting the fatigue experience: a scoping review of fatigue definitions, dimensions, and measures in non-oncologic medical conditions. Brain Behav Immun Health. 2021.
12. Kuppuswamy A. The fatigue conundrum. Brain. 2017.
13. Boksem MAS, Tops M. Mental fatigue: costs and benefits. Brain Res Rev. 2008.
14. Allen PJ. Creatine metabolism and psychiatric disorders: does creatine supplementation have therapeutic value? Neurosci Biobehav Rev. 2012.
15. Targum SD, Fava M. Fatigue as a residual symptom of depression. Innov Clin Neurosci. 2011.
16. Norheim KB, Jonsson G, Omdal R. Biological mechanisms of chronic fatigue. Rheumatology. 2011.